nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2014 | Review Article

Highlights of the 26th EANM 2013 congress in Lyon: new horizons and further

verfasst von: Frank Bengel, Rachele Bonfiglioli, Stefano Fanti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The 26th European Association of Nuclear Medicine (EANM) annual congress was held in Lyon, France, under the chairmanship of Professor Dominique LeGuludec. The congress was attended by more than 5,200 participants, with about one-quarter coming from outside Europe. This review summarizes the major scientific contributions which were selected from the more than 1,700 submitted abstracts, and presented in the closing highlights session. They covered the diverse areas of nuclear medicine, with particular focus on oncology, cardiovascular science and neurology. Various innovations were reported regarding imaging methodology, physics, radiopharmaceuticals and chemistry. Novel radionuclide applications in both diagnosis and therapy were investigated and described, triggering strong interest from the many professionals involved. Significant progress has been demonstrated in the clinical use of existing nuclear medicine procedures, and a number of new applications are under development in preclinical and early clinical stages. The congress was a unique opportunity to get a thorough update on this research.

Zoccarato O, Scabbio C, De Ponti E, et al. Evaluation of the iterative reconstruction algorithms with resolution recovery for reducing patient dose in MPI: transmural defect contrast and left-ventricular wall thickness. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:109.

Caobelli F, Pizzocaro C, Massetti V, et al. Possible use of IQ-SPECT protocol in myocardial perfusion imaging in the evaluation of patients with suspected or known coronary artery disease: preliminary results. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:148.

Bailliez A, Blaire T, Legallois D, et al. Global and regional LV function assessment using two different semiconductor cadmium zinc telluride (CZT) cameras: a dynamic cardiac phantom study compared to conventional gamma camera with cardiofocal collimators. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:148.

van Dalen J, van Osch J, Mouden M, et al. Dose reduction of CT-based attenuation correction in myocardial perfusion CZT-SPECT using iterative CT reconstruction. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:222.

Fukuzawa S, Sugioka J, Ikeda A, et al. Very high coronary calcium score confers high diagnostic added value for detecting coronary artery disease in patients with normal myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:136.

Cozar Santiago M, Garcia Gonzalez P, Estornell Erill J, et al. Combined cardiac magnetic resonance and I-123 MIBG imaging improves risk stratification in patients evaluated for cardiac defibrillator implantation. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:170.

Fiz F, Piccardo A, Picori L, et al. Pathophysiology of calcium deposition as a marker of the ongoing aortic plaque: an 18F-fluoride PET study. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:118.

Hyafil F, Tran Dinh A, Ben Azzouna R, et al. Detection of apoptotic cells in atherosclerotic plaques of rabbits with the PET radiotracer 18F-ML-10. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:119.

Wedel S, Kranert TW, Chodacki A, et al. Updated analysis of radium-223 dichloride (Ra-223) impact on survival, safety, and skeletal-related events in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:190.

10.

Widmark A, Helle SI, James N, et al. Hematologic safety profile of radium-223 dichloride (Ra-223) from the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:189.

11.

Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.PubMedCrossRef

12.

Vallabhajosula S, Nikolopoulou A, Solnes L, et al. Clinical evaluation of a simple kit formulation for the preparation of 99mTc-MIP-1404 for prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:246.

13.

Vallabhajosula S, Green D, Osborne JR, et al. Prostate cancer imaging using a PSMA-targeted small-molecule, 99mTc-MIP-1404: a phase I clinical study in patients undergoing radical prostatectomy. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:415.

14.

Kulkarni HR, Baum RP, Wester H, et al. Biodistribution of Ga-68 labelled prostate specific membrane antigen ligand Glu-NH-CO-NH-Lys-(Ahx)-[68Ga (HBED-CC)] in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:412.

15.

Weineisen M, Schottelius M, Simecek J, et al. New chelator-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:258.

16.

Andreolli E, Al-Momani E, Baur B, et al. Radiosynthesis of [68Ga]Ga-Df-DUPA-Pep as a PSMA ligand. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:323.

17.

Baur B, Al-Momani E, Andreolli E, et al. Synthesis and Zr-89 labeling of Df-DUPA-Pep: A new peptide ligand for molecular imaging of prostate carcinoma. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:191.

18.

Chatalic KLS, Franssen GM, McBride WJ, et al. Preclinical evaluation of Al18F- and 68Ga-labeled GRPR-antagonist for PET imaging of gastrin-releasing peptide receptor expression in prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:115.

19.

Naumann RW, Harb W, Symanowski J, et al. Can 99mTc-etarfolatide (EC20) SPECT imaging identify ovarian cancer patients who are most likely to benefit from folate-receptor-targeted agent vintafolide (EC145). Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:415.

20.

Müller C, Reber J, Haller S, et al. Investigation of 177Lu-folate based radionuclide tumor therapy in combination with pemetrexed. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:121.

21.

Müller C, Bunka M, Reber J, et al. Promising prospects for PET imaging with scandium-44: cyclotron production and preclinical evaluation in tumor-bearing mice. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:116.

22.

Al-Jammaz I, Al-Otaibi B, Amer S, et al. Synthesis and in vitro and in vivo evaluation of iodine-124-labeled folates: potential PET radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:258.

23.

Muselaers CHJ, Bos DL, Mulders PFA, et al. Lutetium-177-G250 radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:288.

24.

Orlova A, Malm M, Lindberg H, et al. Feasibility of radionuclide imaging of HER3-expressing tumours using technetium-99m labeled Affibody molecules. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:185.

25.

Wester H, Keller U, Beer AB, et al. [68Ga]CPCR4.2-PET for imaging of CXCR4-chemokine receptors opens a new and exciting field of clinical research. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:152.

26.

Soussan M, Orlhac F, Boubaya M, et al. FDG-PET/CT textural features in triple negative breast tumors. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:213.

27.

Tixier F, Hatt M, Valla C, et al. Shape indices derived from baseline 18F-FDG PET images can predict response to concomitant radio-chemotherapy in esophageal cancer. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:210.

28.

Vriens D, Adang EMM, Netea-Maier RT, et al. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:239.

29.

Schollaert P, Crott R, Bertrand C, et al. A systematic review of the predictive value of 18FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:363.

30.

Colombié M, Bailly C, Rusu D, et al. Impact of 18F-flurocholine PET/CT in therapeutic strategy of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:162.

31.

Giovacchini G, Picchio M, Garcia-Parra R, et al. [11C]Choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:163.

32.

Kirienko M, Passoni N, Suardi N, et al. Accuracy of [11C]choline PET/CT in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathological-validated series. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:163.

33.

Siepmann S, Brömme J, Arnold A, et al. FDG-PET/CT in the assessment of retro- and parapharyngeal metastases in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:251.

34.

Caicedo C, García-Velloso M, Lozano M, et al. Role of [18F]-FDG-PET-CT in prediction of KRAS and EGFR molecular profile in advanced non-small-cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:223.

35.

de Groot EH, de Jong JR, Dierckx RAJO, et al. Impact of PSF and ToF on the EANM procedure guideline for tumour PET imaging. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:132.

36.

Quak E, Hovhannisyan N, Fruchart C, et al. Prospective evaluation in NHL patients of a strategy to minimise reconstruction dependent variation in SUV. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:209.

37.

Del Sole A, Lecchi M, Gaito S, et al. An international multicentre comparison of true administered F-18 radioactivity in patients undergoing [F-18]FDG-PET exams. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:260.

38.

Santiago-Ribeiro MJ, Vercouillie J, Cottier JP, et al. Microglia activation after acute stroke demonstrated using 18F-DPA-714 PET. Correlation with MRI. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:208.

39.

Plotkin M, Grachev ID, Hauser RA, et al. DaTSCANTM (ioflupane I123 injection) for prediction of clinical diagnosis of early Parkinsonian syndromes: sensitivity, specificity, positive and negative predictive values, and accuracy. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:230.

40.

Pitkonen M, Hippeläinen E, Raki M, et al. Imaging serotonin and dopamine transporters with dynamic 123I-β-CIT SPECT in mouse brain. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:413.

41.

Hatashita S, Yamasaki H, Suzuki Y, et al. [18F] Flutemetamol amyloid-beta PET imaging compared with [11C] PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:419.

42.

Dicken V, Weiler F, Geisler BS, et al. Automated analysis of 18F-florbetaben PET scans. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:181.

43.

Hutton C, Declerck J, Mintun MA, et al. Quantification of florbetapir F18 PET: comparison of two methods. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:182.

44.

Yousefi BH, Förster S, Manook A, et al. Imaging of amyloid deposition in Alzheimer’s disease using a novel radioligand [18F]FIBT: preclinical and first clinical results. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:254.

45.

Ahmad RU, Bourgeois S, Postnov A, et al. Human brain PET imaging of PDE10A in Parkinson’s and Huntington’s disease. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:231.

46.

van der Weg W, Brom M, Janssen MJR, et al. Quantification of the pancreatic beta cell mass with 111In-exendin in patients with type 1 diabetes and healthy controls. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:200.

47.

Szentesi M, Nagy Z, Géher P, et al. A prospective observational study on long-term results of 90Yttrium radiosynoviorthesis of chronic knee synovitis in rheumatoid arthritis and osteoarthritis patients. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:498.

48.

Beatovic S, Jaksic E, Marinkovic J, et al. Standardization of the Diuresis Renography Report by the implementation of International Atomic Energy Agency software package for the analysis of scintigraphic renal dynamic studies. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:105.

Titel: Highlights of the 26th EANM 2013 congress in Lyon: new horizons and further
verfasst von: Frank Bengel
Rachele Bonfiglioli
Stefano Fanti
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2665-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Imaging the future: a report from the Young Daily EANM Forum 2013

FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity

Normal cerebral FDG uptake during childhood

Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer

Suboptimal use of imaging in the new (National Comprehensive Cancer Network) International Prognostic Index for diffuse large B-cell lymphoma

Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography